Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2009. The report serves as a notification to the market regarding the company's issued share capital and total voting rights as of January 31, 2009, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the composition of the company's share capital as of January 31, 2009:
- Total issued Ordinary shares: 5,662,379,039 (25p each).
- Treasury shares held: 474,194,158.
- Total voting rights: 5,188,184,881.
No comparative data for prior periods is included in this specific filing to determine material changes in share count.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document's sole purpose is to inform shareholders of the denominator to be used for calculating notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,188,184,881) against the company's latest annual report to ensure accurate calculation of ownership thresholds.
- Confirm the number of shares held in Treasury (474,194,158) to understand the difference between issued capital and voting capital.
- Note that this filing does not contain operational or financial performance metrics for the period.